PCOLCE2

Summary

PCOLCE2 (procollagen C-endopeptidase enhancer 2, HGNC:8739) is a protein-coding gene on chromosome 3q23, encoding Procollagen C-endopeptidase enhancer 2 (Q9UKZ9). Binds to the C-terminal propeptide of types I and II procollagens and may enhance the cleavage of that propeptide by BMP1.

Enables collagen binding activity; heparin binding activity; and peptidase activator activity. Predicted to act upstream of or within cellular response to leukemia inhibitory factor. Predicted to be located in extracellular region. Predicted to be part of collagen trimer.

Source: NCBI Gene 26577 — RefSeq curated summary.

At a glance

• GWAS associations: 5
• Clinical variants (ClinVar): 87 total
• MANE Select transcript: NM_013363

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:8739
Approved symbol	PCOLCE2
Name	procollagen C-endopeptidase enhancer 2
Location	3q23
Locus type	gene with protein product
Status	Approved
Aliases	PCPE2
Ensembl gene	ENSG00000163710
Ensembl biotype	protein_coding
OMIM	607064
Entrez	26577

Gene structure

Transcript identifiers

Ensembl transcripts: 16 — 8 protein_coding, 3 protein_coding_CDS_not_defined, 3 retained_intron, 2 nonsense_mediated_decay

ENST00000295992, ENST00000461818, ENST00000470310, ENST00000470795, ENST00000480473, ENST00000483454, ENST00000483986, ENST00000485766, ENST00000493733, ENST00000495732, ENST00000648195, ENST00000890789, ENST00000918017, ENST00000964678, ENST00000964679, ENST00000964680

RefSeq mRNA: 1 — MANE Select: NM_013363 NM_013363

CCDS: CCDS3127

Canonical transcript exons

ENST00000295992 — 9 exons

Exon	Start	End
ENSE00001077577	142817874	142818465
ENSE00001136473	142888814	142889083
ENSE00003484316	142820878	142821045
ENSE00003500871	142848217	142848472
ENSE00003550725	142838770	142838906
ENSE00003601685	142829692	142829846
ENSE00003602030	142842924	142843048
ENSE00003665621	142823532	142823615
ENSE00003675817	142887669	142887777

Expression profiles

Bgee: expression breadth ubiquitous, 244 present calls, max score 99.76.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 11.4899 / max 788.2511, expressed in 1043 samples.

FANTOM5 promoters (9 alternative TSS)

Promoter ID	TPM avg	Samples expressed
44866	4.0667	684
44860	2.6961	731
44862	1.9296	326
44859	1.1021	389
44864	0.5527	197
44863	0.5476	188
44861	0.2130	104
44865	0.1967	86
44858	0.1852	112

Top tissues by expression

284 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
calcaneal tendon	UBERON:0003701	99.76	gold quality
tibia	UBERON:0000979	99.61	gold quality
synovial joint	UBERON:0002217	99.44	gold quality
renal glomerulus	UBERON:0000074	99.09	gold quality
tendon of biceps brachii	UBERON:0008188	99.09	gold quality
right coronary artery	UBERON:0001625	99.00	gold quality
metanephric glomerulus	UBERON:0004736	98.95	gold quality
tendon	UBERON:0000043	98.74	gold quality
pericardium	UBERON:0002407	98.50	gold quality
right atrium auricular region	UBERON:0006631	98.47	gold quality
descending thoracic aorta	UBERON:0002345	98.42	gold quality
cardiac atrium	UBERON:0002081	98.31	gold quality
coronary artery	UBERON:0001621	98.26	gold quality
left coronary artery	UBERON:0001626	98.21	gold quality
thoracic aorta	UBERON:0001515	98.04	gold quality
ascending aorta	UBERON:0001496	98.01	gold quality
adipose tissue	UBERON:0001013	97.28	gold quality
saphenous vein	UBERON:0007318	97.22	gold quality
vena cava	UBERON:0004087	97.20	gold quality
parietal pleura	UBERON:0002400	97.11	gold quality
apex of heart	UBERON:0002098	97.05	gold quality
connective tissue	UBERON:0002384	97.04	gold quality
subcutaneous adipose tissue	UBERON:0002190	96.97	gold quality
aorta	UBERON:0000947	96.80	gold quality
adipose tissue of abdominal region	UBERON:0007808	96.56	gold quality
omental fat pad	UBERON:0010414	96.44	gold quality
peritoneum	UBERON:0002358	96.40	gold quality
trachea	UBERON:0003126	96.36	gold quality
layer of synovial tissue	UBERON:0007616	96.20	gold quality
urethra	UBERON:0000057	96.18	gold quality

Single-cell (SCXA)

Detected in 5 experiment(s), a significant marker in 4.

Experiment	Marker?	Max mean expression
E-MTAB-8322	yes	2398.65
E-CURD-119	yes	26.28
E-HCAD-1	yes	17.34
E-GEOD-111727	no	31.73
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

26 targeting PCOLCE2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-32-5P	99.98	75.21	1964
HSA-MIR-92A-3P	99.98	75.21	1960
HSA-MIR-92B-3P	99.98	75.25	1955
HSA-MIR-25-3P	99.98	74.60	1817
HSA-MIR-363-3P	99.98	74.72	1821
HSA-MIR-367-3P	99.98	74.83	1819
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-380-3P	99.89	70.18	1978
HSA-MIR-4503	99.85	71.45	1869
HSA-MIR-489-3P	99.80	66.46	839
HSA-MIR-4694-3P	99.79	69.53	2640
HSA-MIR-4325	99.49	72.20	1342
HSA-MIR-3171	99.49	69.06	776
HSA-MIR-377-3P	99.37	70.18	1905
HSA-MIR-3925-5P	99.21	67.90	1466
HSA-MIR-4709-3P	98.88	68.04	1594
HSA-MIR-4477A	98.83	69.75	2952
HSA-MIR-501-5P	98.77	68.88	1328
HSA-MIR-500A-5P	98.76	69.13	1241
HSA-MIR-3611	98.76	68.76	1290
HSA-MIR-6761-5P	98.71	68.03	1504
HSA-MIR-6792-5P	98.39	68.16	1330
HSA-MIR-6881-3P	98.04	68.24	1777
HSA-MIR-7703	97.64	67.00	965
HSA-MIR-7161-3P	96.79	68.79	798
HSA-MIR-4268	94.45	64.09	819

Literature-anchored findings (GeneRIF, showing 4)

• Assignment of Pcolce2 gene, which encodes procollagen C-proteinase enhancer protein 2, to human chromosome 3q23. (PMID:12063410)
• PCPE2 is shown to be a glycoprotein that differs markedly in the nature of its glycosylation from that of PCPE1 (PMID:12393877)
• Data indicate that PCPE2 accelerates the proteolytic processing of pro-apolipoprotein (apo) AI by enhancing the cleavage of the hexapeptide extension present at the N terminus of apoAI. (PMID:19237735)
• Procollagen C-endopeptidase protein 2, atherosclerosis and HDL cholesteryl ester catabolism. [Review] (PMID:26218419)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	pcolce2a	ENSDARG00000008450
danio_rerio	pcolce2b	ENSDARG00000055575
mus_musculus	Pcolce2	ENSMUSG00000015354
rattus_norvegicus	PCOLCE2	ENSRNOG00000046848

Paralogs (35): NRXN3 (ENSG00000021645), TLL1 (ENSG00000038295), CP (ENSG00000047457), DCBLD2 (ENSG00000057019), HEPH (ENSG00000089472), TLL2 (ENSG00000095587), NRP1 (ENSG00000099250), PCOLCE (ENSG00000106333), CNTNAP3 (ENSG00000106714), CUBN (ENSG00000107611), CNTNAP1 (ENSG00000108797), NRXN2 (ENSG00000110076), MEP1A (ENSG00000112818), NRP2 (ENSG00000118257), CUZD1 (ENSG00000138161), MFGE8 (ENSG00000140545), MEP1B (ENSG00000141434), PDGFC (ENSG00000145431), CNTNAP4 (ENSG00000152910), CNTNAP3B (ENSG00000154529), CNTNAP5 (ENSG00000155052), CDCP2 (ENSG00000157211), EDIL3 (ENSG00000164176), NETO1 (ENSG00000166342), BMP1 (ENSG00000168487), PDGFD (ENSG00000170962), NETO2 (ENSG00000171208), CNTNAP2 (ENSG00000174469), NRXN1 (ENSG00000179915), HEPHL1 (ENSG00000181333), F8 (ENSG00000185010), ASTL (ENSG00000188886), F5 (ENSG00000198734), MFRP (ENSG00000235718), CNTNAP3C (ENSG00000283378)

Protein

Protein identifiers

Procollagen C-endopeptidase enhancer 2 — Q9UKZ9 (reviewed: Q9UKZ9)

Alternative names: Procollagen COOH-terminal proteinase enhancer 2

All UniProt accessions (5): A0A3B3ITE8, C9JYX9, Q9UKZ9, H7C520, H7C5D5

UniProt curated annotations — full annotation on UniProt →

Function. Binds to the C-terminal propeptide of types I and II procollagens and may enhance the cleavage of that propeptide by BMP1.

Subunit / interactions. Interacts with heparin with high affinity, and type I or II collagen.

Subcellular location. Secreted.

Tissue specificity. Highly expressed in the heart, trabecular meshwork, pituitary gland, bladder, mammary gland, trachea and placenta and weakly expressed in the brain. Expressed in cartilage.

Post-translational modifications. O-glycosylated; contains sialic acid.

RefSeq proteins (1): NP_037495* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000859	CUB_dom	Domain
IPR001134	Netrin_domain	Domain
IPR008993	TIMP-like_OB-fold	Homologous_superfamily
IPR018933	Netrin_module_non-TIMP	Domain
IPR035814	NTR_PCOLCE	Domain
IPR035914	Sperma_CUB_dom_sf	Homologous_superfamily

Pfam: PF00431, PF01759

UniProt features (15 total): disulfide bond 7, domain 3, sequence variant 2, signal peptide 1, chain 1, glycosylation site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9UKZ9-F1	82.00	0.46

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (7): 297–364, 301–367, 312–415, 33–59, 86–107, 154–181, 208–231

Glycosylation sites (1): 355

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-1650814	Collagen biosynthesis and modifying enzymes

MSigDB gene sets: 164 (showing top): GSE18804_SPLEEN_MACROPHAGE_VS_BRAIN_TUMORAL_MACROPHAGE_DN, GSE18804_SPLEEN_MACROPHAGE_VS_TUMORAL_MACROPHAGE_DN, GOBP_RESPONSE_TO_PEPTIDE, GAUSSMANN_MLL_AF4_FUSION_TARGETS_A_DN, ACEVEDO_NORMAL_TISSUE_ADJACENT_TO_LIVER_TUMOR_DN, CHANDRAN_METASTASIS_DN, CLASPER_LYMPHATIC_VESSELS_DURING_METASTASIS_DN, SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM4, BILD_E2F3_ONCOGENIC_SIGNATURE, RIGGI_EWING_SARCOMA_PROGENITOR_DN, SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_UP, MCBRYAN_PUBERTAL_BREAST_5_6WK_UP, ONDER_CDH1_TARGETS_2_UP, RICKMAN_HEAD_AND_NECK_CANCER_A, GOMF_GLYCOSAMINOGLYCAN_BINDING

GO Biological Process (1): cellular response to leukemia inhibitory factor (GO:1990830)

GO Molecular Function (4): collagen binding (GO:0005518), heparin binding (GO:0008201), peptidase activator activity (GO:0016504), protein binding (GO:0005515)

GO Cellular Component (1): extracellular region (GO:0005576)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Collagen formation	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular response to cytokine stimulus	1
response to leukemia inhibitory factor	1
protein-containing complex binding	1
glycosaminoglycan binding	1
sulfur compound binding	1
enzyme activator activity	1
peptidase activity	1
peptidase regulator activity	1
binding	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1102 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PCOLCE2	PLS1	Q14651	826
PCOLCE2	NTSR1	P30989	759
PCOLCE2	TRPC1	P48995	666
PCOLCE2	SCARB1	Q8WTV0	507
PCOLCE2	COL1A1	P02452	459
PCOLCE2	GPC6	Q9Y625	449
PCOLCE2	THBS1	P07996	442
PCOLCE2	COL6A1	P12109	438
PCOLCE2	CMTM4	Q8IZR5	425
PCOLCE2	CLU	P10909	420
PCOLCE2	CILP	O75339	412
PCOLCE2	FOXL2NB	Q6ZUU3	411
PCOLCE2	COL6A2	P12110	410
PCOLCE2	SERPINH1	P29043	400
PCOLCE2	PI16	Q6UXB8	390

IntAct

26 interactions, top by confidence:

A	B	Type	Score
OLFM1	OLFM2	psi-mi:“MI:0914”(association)	0.640
PCOLCE2	ZWINT	psi-mi:“MI:0915”(physical association)	0.560
PCOLCE2	ZWINT	psi-mi:“MI:0914”(association)	0.560
DKK3	NME4	psi-mi:“MI:0914”(association)	0.530
ALPG	ALPP	psi-mi:“MI:0914”(association)	0.530
SLC25A51	PCOLCE2	psi-mi:“MI:0915”(physical association)	0.400
TRADD	HNRNPCL2	psi-mi:“MI:0914”(association)	0.350
SCGB2A2	GXYLT2	psi-mi:“MI:0914”(association)	0.350
SUSD4	CCDC85C	psi-mi:“MI:0914”(association)	0.350
PSG1	IKBKB	psi-mi:“MI:0914”(association)	0.350
OLFM1		psi-mi:“MI:0914”(association)	0.350
rep	MYCBP2	psi-mi:“MI:0914”(association)	0.350
PDGFRA	GXYLT2	psi-mi:“MI:0914”(association)	0.350
CCL3	KRBA1	psi-mi:“MI:0914”(association)	0.350
ST14	LIPT2	psi-mi:“MI:0914”(association)	0.350
SCGB2A2	RTL8C	psi-mi:“MI:0914”(association)	0.350
CCL3L1	QSOX1	psi-mi:“MI:0914”(association)	0.350
TMPRSS13	TOR1A	psi-mi:“MI:0914”(association)	0.350
HPN	TOR1A	psi-mi:“MI:0914”(association)	0.350
VNN1	SMAD7	psi-mi:“MI:0914”(association)	0.350
PCOLCE2	KLK7	psi-mi:“MI:0914”(association)	0.350
AFG2A	ESYT2	psi-mi:“MI:0914”(association)	0.350
AFG2B	MMP24OS	psi-mi:“MI:0914”(association)	0.350
SLC17A9	PIPSL	psi-mi:“MI:0914”(association)	0.350

BioGRID (36): STRN4 (Affinity Capture-MS), ZWINT (Affinity Capture-MS), STRN3 (Affinity Capture-MS), STRN (Affinity Capture-MS), PCOLCE2 (Affinity Capture-MS), PCOLCE2 (Affinity Capture-MS), PCOLCE2 (Affinity Capture-MS), PCOLCE2 (Affinity Capture-MS), PCOLCE2 (Affinity Capture-MS), PCOLCE2 (Affinity Capture-MS), ZWINT (Affinity Capture-MS), PCOLCE2 (Affinity Capture-MS), PCOLCE2 (Affinity Capture-MS), PCOLCE2 (Affinity Capture-MS), PCOLCE2 (Synthetic Lethality)

ESM2 similar proteins: A8WCC4, D3ZTD8, J3RZ81, O14786, O35276, O35375, O57472, O60462, P07224, P07225, P21956, P28824, P48740, P53813, P60755, P60756, P70490, P79795, P85171, P97333, P98064, P98118, Q08761, Q0PMG2, Q0WYX8, Q12866, Q13591, Q16819, Q28520, Q2VWQ2, Q60805, Q62217, Q62919, Q7Z553, Q86TH1, Q8BR86, Q8CHN8, Q8CI19, Q8IZU9, Q8NFP4

Diamond homologs: A0A0C5PRQ1, A0FKN6, A0JNA2, A8Q2D1, C6K2K4, C9D7R3, D2KBH9, D5FM34, D5FM37, D5FM38, K7Z9Q9, O16977, O17264, O35276, O35375, O43897, O57382, O57460, O60462, O60494, O70244, P07584, P0DM61, P0DM62, P13497, P28825, P28826, P31579, P31580, P31581, P42674, P55112, P55113, P55114, P55115, P84748, P91828, P98060, P98061, P98068

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

87 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	77
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1797 predictions. Top by Δscore:

Variant	Effect	Δscore
3:142820874:TCA:T	donor_loss	1.0000
3:142820875:CA:C	donor_loss	1.0000
3:142820876:ACCTC:A	donor_loss	1.0000
3:142820877:CCT:C	donor_gain	1.0000
3:142821041:TAATA:T	acceptor_gain	1.0000
3:142821042:AATA:A	acceptor_gain	1.0000
3:142821043:ATA:A	acceptor_gain	1.0000
3:142821044:TA:T	acceptor_gain	1.0000
3:142821044:TAC:T	acceptor_loss	1.0000
3:142821045:AC:A	acceptor_loss	1.0000
3:142821046:C:CC	acceptor_gain	1.0000
3:142821047:T:C	acceptor_loss	1.0000
3:142829690:AC:A	donor_gain	1.0000
3:142829691:CC:C	donor_gain	1.0000
3:142838761:GCTAC:G	donor_loss	1.0000
3:142838762:CTACT:C	donor_loss	1.0000
3:142838763:TACTT:T	donor_loss	1.0000
3:142838764:ACT:A	donor_loss	1.0000
3:142838765:CTT:C	donor_loss	1.0000
3:142838766:T:TC	donor_loss	1.0000
3:142838767:T:TC	donor_loss	1.0000
3:142838768:A:AC	donor_gain	1.0000
3:142838768:A:G	donor_loss	1.0000
3:142838768:ACG:A	donor_gain	1.0000
3:142838769:C:CA	donor_gain	1.0000
3:142838769:CG:C	donor_gain	1.0000
3:142838769:CGC:C	donor_gain	1.0000
3:142838769:CGCA:C	donor_gain	1.0000
3:142838769:CGCAG:C	donor_gain	1.0000
3:142838796:T:A	donor_gain	1.0000

AlphaMissense

2729 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:142829778:C:T	G260E	0.999
3:142829779:C:A	G260W	0.999
3:142829820:A:G	L246P	0.999
3:142838848:T:A	D211V	0.999
3:142838849:C:A	D211Y	0.999
3:142838849:C:G	D211H	0.999
3:142842948:C:A	W183C	0.999
3:142842948:C:G	W183C	0.999
3:142842954:A:C	C181W	0.999
3:142842955:C:G	C181S	0.999
3:142842955:C:T	C181Y	0.999
3:142842956:A:G	C181R	0.999
3:142842956:A:T	C181S	0.999
3:142848255:A:C	F137C	0.999
3:142848255:A:G	F137S	0.999
3:142848345:C:G	C107S	0.999
3:142848345:C:T	C107Y	0.999
3:142848346:A:T	C107S	0.999
3:142848399:T:A	D89V	0.999
3:142848399:T:G	D89A	0.999
3:142848400:C:A	D89Y	0.999
3:142848400:C:G	D89H	0.999
3:142848447:A:G	L73P	0.999
3:142887678:C:A	W61C	0.999
3:142887678:C:G	W61C	0.999
3:142887685:C:G	C59S	0.999
3:142887686:A:T	C59S	0.999
3:142829775:A:G	F261S	0.998
3:142829799:T:A	D253V	0.998
3:142829808:A:G	F250S	0.998

dbSNP variants (sampled 300 via entrez): RS1000010847 (3:142824002 G>A), RS1000012598 (3:142873890 C>T), RS1000075500 (3:142880348 T>C,G), RS1000075550 (3:142829624 T>A,C), RS1000079428 (3:142867641 G>A), RS1000084425 (3:142844721 A>G), RS1000144185 (3:142873557 G>T), RS1000148721 (3:142879452 A>G), RS1000260482 (3:142873813 C>G,T), RS1000324721 (3:142890943 C>A), RS1000401078 (3:142824123 A>C,G), RS1000485097 (3:142854610 T>C), RS1000531441 (3:142829935 C>A,T), RS1000617673 (3:142825744 A>G), RS1000628434 (3:142831454 A>C)

Disease associations

OMIM: gene MIM:607064 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

5 associations (top):

Study	Trait	p-value
GCST002712_1	Red blood cell fatty acid levels	1.000000e-10
GCST006585_1677	Blood protein levels	3.000000e-59
GCST006979_304	Heel bone mineral density	2.000000e-10
GCST007096_209	Pulse pressure	4.000000e-11
GCST90011898_151	Alanine aminotransferase levels	3.000000e-11

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0006808	arachidonic acid measurement
EFO:0009270	heel bone mineral density
EFO:0005763	pulse pressure measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

50 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Estradiol	affects cotreatment, decreases expression, increases expression, increases reaction	4
Tetrachlorodibenzodioxin	affects cotreatment, decreases expression, increases expression	4
trichostatin A	affects cotreatment, increases expression	3
sodium arsenite	increases abundance, increases expression, decreases expression, affects cotreatment	3
Valproic Acid	affects expression, increases expression	3
Vorinostat	affects cotreatment, increases expression	2
Panobinostat	affects cotreatment, increases expression	2
Benzo(a)pyrene	affects methylation, decreases expression	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
Cyclosporine	decreases expression	2
Aflatoxin B1	affects methylation, decreases expression	2
aristolochic acid I	decreases expression	1
manganese chloride	increases abundance, increases expression, affects cotreatment	1
potassium chromate(VI)	increases expression	1
aflatoxin B2	decreases methylation	1
avobenzone	increases expression	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression, decreases expression	1
ICG 001	decreases expression	1
abrine	decreases expression	1
2,2’,4,4’-tetrabromodiphenyl ether	increases expression	1
dorsomorphin	affects cotreatment, increases expression, decreases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	increases expression	1
Temozolomide	decreases expression	1
Pioglitazone	increases expression	1
Sunitinib	decreases expression	1
Zoledronic Acid	decreases expression	1
Arsenic Trioxide	decreases expression	1
Acetaminophen	decreases expression	1
Air Pollutants	decreases expression, increases abundance	1

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B2A3	Abcam HeLa PCOLCE2 KO	Cancer cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.